RxDoctor Payments Data

Kenneth Goolsby, MD

Psychiatry · Gainesville, GANPI 1366457012

Payments from drug & device makers

$7,016in general payments, 2019–2025

Across 430 payments — averaging $16.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$955
  • Otsuka America Pharmaceutical, Inc.$722
  • Johnson & Johnson$617
  • Takeda Pharmaceuticals U.S.A., Inc.$606
  • Vanda Pharmaceuticals Inc.$522
  • Supernus Pharmaceuticals, Inc.$414
  • plus $3K from 23 others

What the payments were for

  • Food & beverage$6,96999%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$7,016 in reported general payments places this provider in the 85th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$322,311
Medicare patients
287
Services billed
2,917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl37$74,897
TrintellixVortioxetine Hydrobromide59$44,718
AuvelityDextromethorphan Hbr/Bupropion19$23,799
VyvanseLisdexamfetamine Dimesylate58$22,685
Lurasidone Hcl72$19,287
BelsomraSuvorexant27$14,213
Adderall XrDextroamphetamine/Amphetamine30$9,413
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine315$9,048
Lisdexamfetamine Dimesylate36$7,051
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine122$5,584
Buprenorphine Hcl52$4,423
Bupropion XlBupropion Hcl156$4,395
Alprazolam650$4,150
Methylphenidate Hcl124$4,050
Clomipramine Hcl12$3,895

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$955$74,89737 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$606$67,404117 claims
Axsome Therapeutics, Inc.Auvelity$199$23,79919 claims
MerckBelsomra$79$14,21327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →